Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB -3.04%10 FCF Margin % is -4,627.85% as of Mar. 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 950 Biotechnology companies, Upstream Bio ranks worse than 88.95% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Upstream Bio's Free Cash Flow for the
three
months ended in Mar. 2026 was $-47.85 Mil. Upstream Bio's Revenue for the
three
months ended in Mar. 2026 was $1.03 Mil. Therefore, Upstream Bio's FCF Margin % for the quarter that ended in Mar. 2026 was -4,627.85%.
The historical rank and industry rank for Upstream Bio's FCF Margin % or its related term are showing as below:
UPB'
s FCF Margin % Range Over the Past 10 Years
Min: -4675.54 Med: -2058.93 Max: -1576.16
Current: -4213.18
During the past 4 years, the highest FCF Margin % of Upstream Bio was -1576.16%. The lowest was -4675.54%. And the median was -2058.93%.
UPB's FCF Margin % is ranked worse than 88.95% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs UPB: -4213.18
Upstream Bio FCF Margin % Related Terms
Upstream Bio FCF Margin % Historical Data
* Premium members only.
The historical data trend for Upstream Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Upstream Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Upstream Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Upstream Bio (UPB) has a FCF Margin % of -4,627.85% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Upstream Bio and its competitors. According to the industry distribution chart, Upstream Bio ranks #845 out of 950 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Upstream Bio's FCF Margin % too high?
Upstream Bio's current FCF Margin % is -4,627.85%. Based on the distribution chart, Upstream Bio ranks #845 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's FCF Margin % compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #845 out of 950 companies for FCF Margin %. This places Upstream Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Upstream Bio and its competitors. Upstream Bio's current FCF Margin % is -4,627.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current FCF Margin % of -4,627.85%. The current FCF Margin % is -4,627.85%. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Upstream Bio (UPB), the current FCF Margin % is -4,627.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
